Zhang Zemin's research team and collaborators reveal the mechanism of anti-PD-1 immunotherapy in lung cancer

On December 23, 2021, Peking University Biomedical Frontier Innovation Center (BIOPIC), School of Life Sciences, Beijing Future Gene Diagnosis Advanced Innovation Center (ICG) Zhang Zemin's research group and 301 Hospital Han Weidong's research group published in the international journal Nature Cancer A research paper entitled " Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer ", proposed the concept of clonal revival and revealed PD-1 The mechanism of action of antibody therapy in lung cancer

Screenshot of the paper

Immunotherapy represented by anti-PD-1 has significantly improved the pattern of cancer treatment, but immunotherapy only works in a part of cancer patients

Figure 1.

Tumor infiltrating T cells include not only tumor-specific T cells that can recognize tumor antigens and kill cancer cells, but also T cells that specifically recognize non-tumor antigens such as influenza viruses, and non-tumor-specific T cells account for a large portion of tumors Proportion ^[1]

The researchers developed a new set of analysis ideas (Figure 1).

There are three possibilities for the increase of tumor-specific T cell precursor cells after effective treatment: 1.

In addition, the Howard Chang research group of Stanford University proposed the concept of clonal replacement, which believed that the clonal types of tumor-specific T cells in tumors after treatment were newly emerged ^[7]

Figure 2.

Baolin Liu, a doctoral student from the BIOPIC/School of Life Sciences at Peking University, Dr.

references:

[1] Simoni et al.

[2] Caushi et al.

[3] Oliveira et al.

[4] Ahmadzadehet al.

[5] van der Leun et al.

[6] Pauken et al.

[7] Yost et al.
, Clonal replacement of tumor-specific T cells following PD-1 blockade, Nat.
Med.
(2019).